Join

Compare · PFE vs PTIX

PFE vs PTIX

Side-by-side comparison of Pfizer Inc. (PFE) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PFE and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • PFE is the larger of the two at $153.59B, about 8234.5x PTIX ($18.7M).
  • Over the past year, PFE is up 17.1% and PTIX is down 75.4% - PFE leads by 92.5 points.
  • PFE has been more active in the news (10 items in the past 4 weeks vs 1 for PTIX).
  • PFE has more recent analyst coverage (25 ratings vs 1 for PTIX).
PerformancePFE+17.13%PTIX-75.41%
2025-04-28+0.00%2026-04-24
MetricPFEPTIX
Company
Pfizer Inc.
Protagenic Therapeutics Inc.
Price
$26.98+1.20%
$0.73-44.06%
Market cap
$153.59B
$18.7M
1M return
-1.21%
+0.00%
1Y return
+17.13%
-75.41%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
10
1
Recent ratings
25
1
PFE

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PTIX

Protagenic Therapeutics Inc.

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Latest PFE

Latest PTIX